Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,835 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM, Badesch DB, Ghofrani HA, et al. · N Engl J Med · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
Humbert M, McLaughlin VV, Badesch DB, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Humbert M, McLaughlin V, Gibbs JSR, et al. · N Engl J Med · 2021Clinical Trial, Phase II, Multicenter Study
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
McLaughlin VV, Hoeper MM, Badesch DB, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med · 2024Systematic Review, Meta-Analysis
- Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, et al. · Circulation · 2009Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.
Ershed M, da Silva ABN, Felix de Farias Dos Santos AC, et al. · Expert Rev Respir Med · 2025Meta-Analysis, Systematic Review
- Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Humbert M, McLaughlin V, Gibbs JSR, et al. · Eur Respir J · 2023Randomized Controlled Trial, Clinical Trial, Phase II
- Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E, Jansa P, Fan F, et al. · J Am Coll Cardiol · 2024Randomized Controlled Trial, Multicenter Study
- Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
Frantz RP, McLaughlin VV, Sahay S, et al. · Lancet Respir Med · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, et al. · N Engl J Med · 2013Clinical Trial, Phase III, Multicenter Study
- Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).
Montani D, McLaughlin VV, Gibbs JSR, et al. · Am J Respir Crit Care Med · 2025Clinical Trial, Phase II, Randomized Controlled Trial
- Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. · Am J Respir Crit Care Med · 2020Clinical Trial, Research Support, Non-U.S. Gov't
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, et al. · J Am Coll Cardiol · 2021Clinical Trial, Phase III, Comparative Study
- Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.
Berger RMF, Dunbar Ivy D, Borissoff JI, et al. · J Pediatr · 2026Randomized Controlled Trial, Multicenter Study
- Drug-associated pulmonary arterial hypertension.
McGee M, Whitehead N, Martin J, et al. · Clin Toxicol (Phila) · 2018Systematic Review
- Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized PADN-CFDA Trial.
Zhang H, Wei Y, Zhang C, et al. · JACC Cardiovasc Interv · 2022Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
Shalabi L, Tabassum S, Al Zoubi BM, et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025Systematic Review, Meta-Analysis
- Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials.
Abdulelah M, Ezenna C, Jenil-Franco A, et al. · Vascul Pharmacol · 2025Meta-Analysis, Systematic Review
- Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Simonneau G, Barst RJ, Galie N, et al. · Am J Respir Crit Care Med · 2002Clinical Trial, Multicenter Study
- Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis.
Pitre T, Desai K, Mah J, et al. · Ann Am Thorac Soc · 2024Systematic Review, Comparative Study
- Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Tremblay É, Gosselin C, Mai V, et al. · Circulation · 2022Meta-Analysis, Systematic Review
- Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.
Grynblat J, Khouri C, Hlavaty A, et al. · Eur Respir J · 2024Meta-Analysis, Systematic Review
- Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Hoeper MM, Barst RJ, Bourge RC, et al. · Circulation · 2013Multicenter Study, Randomized Controlled Trial
- Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.
Rhodes CJ, Batai K, Bleda M, et al. · Lancet Respir Med · 2019Meta-Analysis, Research Support, N.I.H., Extramural
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.